ViewsML Raises $4.9M for AI-Driven Virtual Biomarker Staining Platform

HIT Consultant – Read More

What You Should Know

The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clinic and Continuum Health Ventures, alongside repeat investors like RiSC Capital and Debiopharm.
The Core Technology: ViewsML is building the world’s first virtual biomarker library. Using artificial intelligence, the platform generates per-cell biomarker spatial insights directly from standard, routine pathology images (H&E slides)—completely eliminating the need for physical laboratory staining (immunohistochemistry or IHC).
The Next Steps: The capital will be used to accelerate the commercialization of the platform, advance clinical validation, and expand engineering teams. ViewsML will publicly showcase the technology at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.

Unlocking the Virtual Biomarker Library

Traditional immunohistochemistry (IHC) and staining workflows have long been a bottleneck in drug development and diagnostics, often requiring days or weeks to produce results. ViewsML is addressing this by building the world’s first virtual biomarker library.

Speed to Insight: The platform extracts per-cell spatial biomarker insights directly from routine pathology images (standard H&E slides) in minutes.
Tissue Preservation: By virtualizing the staining process, the technology preserves scarce tissue samples that would otherwise be consumed by traditional laboratory workflows.
Scalable Computation: The library enables a new paradigm for assay development, shifting immunohistochemistry from a lab-bound process into a high-resolution computational layer.

Strategic Partnerships and Clinical Validation

The partnership with Mayo Clinic and Wittington Ventures (which is backed by the holding company for Loblaw and Shoppers Drug Mart) positions ViewsML to move rapidly into clinical validation.

Target Markets: The platform is designed for use across translational research, diagnostics, clinical trials, and emerging areas like neurodegenerative disease.
Growth Objectives: The new funding will support the growth of ViewsML’s engineering, scientific, and commercial teams to meet rising demand from biopharma and diagnostic organizations.

“We’re building the computational layer for next-generation diagnostics… empowering scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks,” said Kenneth To, CEO of ViewsML.